PMID- 31614574
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-3425 (Print)
IS  - 2076-3425 (Electronic)
IS  - 2076-3425 (Linking)
VI  - 9
IP  - 10
DP  - 2019 Oct 11
TI  - Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study.
LID - 10.3390/brainsci9100272 [doi]
LID - 272
AB  - Background: Safinamide is an approved drug for the treatment of motor 
      fluctuations of Parkinson's Disease (PD) patients with a potential benefit on 
      non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was 
      conducted, in which the clinical effect of safinamide on both motor and NMS was 
      assessed by the Clinical Global Impression of Change scale. Furthermore, we 
      assessed the appearance of adverse events (AEs) and its effect on dyskinesia, 
      that were also recorded in non-fluctuating PD patients and in those previously 
      treated with rasagiline. Results: We included 213 PD patients who received 
      safinamide in addition to their regular levodopa therapy. Thirty-five withdrew 
      prematurely from safinamide, mainly because of AEs. Out of 178, clinical 
      improvement on motor and NMS was found in 76.4% and 26.2%, respectively. A total 
      of 44 reported AEs of mild intensity. We did not find a difference concerning the 
      clinical benefit or AEs when comparing either patients who had or had not been 
      taking Monoamine Oxidase B Inhibitor (MAOB-I) previously or between patients with 
      and without motor complications. Conclusions: Safinamide is an effective and safe 
      add-on to levodopa drug for PD patients. Moreover, safinamide could elicit an 
      additional clinical improvement in PD patients previously treated with other 
      MAOB-I and in non- fluctuating patients with suboptimal motor control.
FAU - Marti-Andres, Gloria
AU  - Marti-Andres G
AUID- ORCID: 0000-0001-6474-8454
AD  - Movement Disorders Unit, Clinica Universidad de Navarra (CUN), 31008 Pamplona, 
      Spain. gmartia@unav.es.
AD  - IdiSNA (Navarra Institute for Health Research), 31008 Pamplona, Spain. 
      gmartia@unav.es.
FAU - Jimenez-Bolanos, Rayco
AU  - Jimenez-Bolanos R
AD  - Movement Disorders Unit, Hospital Universitario Insular de Gran Canaria, 35016 
      Las Palmas de Gran Canaria (HUIGC), Spain. rayco.jb.92@gmail.com.
FAU - Arbelo-Gonzalez, Jose Matias
AU  - Arbelo-Gonzalez JM
AD  - Movement Disorders Unit, Hospital Universitario Insular de Gran Canaria, 35016 
      Las Palmas de Gran Canaria (HUIGC), Spain. jmarbelo@gmail.com.
FAU - Pagonabarraga, Javier
AU  - Pagonabarraga J
AUID- ORCID: 0000-0002-3248-704X
AD  - Movement Disorders Unit, Hospital de la Santa Creu i Sant Pau (HSCSP), 08041 
      Barcelona, Spain. JPagonabarraga@santpau.cat.
FAU - Duran-Herrera, Carmen
AU  - Duran-Herrera C
AD  - Movement Disorders Unit, Hospital Universitario de Badajoz, 06080 Badajoz, Spain. 
      mariacarmenduranherrera@gmail.com.
FAU - Valenti-Azcarate, Rafael
AU  - Valenti-Azcarate R
AUID- ORCID: 0000-0002-1691-6908
AD  - Movement Disorders Unit, Clinica Universidad de Navarra (CUN), 31008 Pamplona, 
      Spain. rvalenti@unav.es.
AD  - IdiSNA (Navarra Institute for Health Research), 31008 Pamplona, Spain. 
      rvalenti@unav.es.
FAU - Luquin, M feminine Rosario
AU  - Luquin MR
AD  - Movement Disorders Unit, Clinica Universidad de Navarra (CUN), 31008 Pamplona, 
      Spain. rluquin@unav.es.
AD  - IdiSNA (Navarra Institute for Health Research), 31008 Pamplona, Spain. 
      rluquin@unav.es.
LA  - eng
GR  - FPU16/02457/FPU grant (Formacion Profesorado Universitario). Spanish Ministry of 
      Science and Innovation (MCINN)/
PT  - Journal Article
DEP - 20191011
PL  - Switzerland
TA  - Brain Sci
JT  - Brain sciences
JID - 101598646
PMC - PMC6826846
OTO - NOTNLM
OT  - Adverse drug event
OT  - Drug-Induced
OT  - Dyskinesia
OT  - Motor complications
OT  - Parkinson's Disease
OT  - Safinamide
COIS- G.M.-A., R.J.-B. and R.V.-A. declare no conflict of interest. J.M.A.-G. has 
      received honoraria from AbbVie, Zambon, Bial and Teva for activities unrelated to 
      the work submitted. C.D.-H. have received honoraria from Sanofi-Genzyme, 
      Novartis, AbbVie and Bial for activities unrelated to the work submitted. J.P. is 
      speaker and member of Scientific Advisory Board of Zambon, UCB and Bial for 
      activities unrelated to the work submitted. M.R.L. have received honoraria from 
      TEVA, Zambon, AbbVie and Bial for activities unrelated to the work submitted.
EDAT- 2019/10/17 06:00
MHDA- 2019/10/17 06:01
PMCR- 2019/10/01
CRDT- 2019/10/17 06:00
PHST- 2019/08/28 00:00 [received]
PHST- 2019/09/29 00:00 [revised]
PHST- 2019/10/09 00:00 [accepted]
PHST- 2019/10/17 06:00 [entrez]
PHST- 2019/10/17 06:00 [pubmed]
PHST- 2019/10/17 06:01 [medline]
PHST- 2019/10/01 00:00 [pmc-release]
AID - brainsci9100272 [pii]
AID - brainsci-09-00272 [pii]
AID - 10.3390/brainsci9100272 [doi]
PST - epublish
SO  - Brain Sci. 2019 Oct 11;9(10):272. doi: 10.3390/brainsci9100272.